Vifor Pharma licenses marketing rights to CCX168 in certain territories
Tuesday, 10 May 2016, ↓ directly to download
Vifor Pharma Licenses Rights to Commercialize ChemoCentryx’s Orally-Administered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets
Vifor Pharma, a company of the Galenica Group, and ChemoCentryx, Inc. (Nasdaq: CCXI), a biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, announced today that Vifor Pharma has licensed rights to commercialize CCX168, a Complement 5a Receptor (C5aR) inhibitor ready for Phase 3 development for orphan and rare renal diseases, in Europe, Canada, Mexico, Central and South America and South Korea.
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
Friday, 23 December 2016
Friday, 9 December 2016
Monday, 28 November 2016
Thursday, 6 October 2016
Friday, 2 September 2016
Head of Corporate Communications
Head Investor Relations